| $376M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $99M |
Buys | $212,650 | 24 | 96 |
Sells | $3,650 | 1 | 4 |
| Roberts Eric W | CHIEF BUSINESS OFFICER | 16 | $147,271 | 0 | $0 | $147,271 |
| Hebbar Sudarshan | Chief Medical Officer | 3 | $43,323 | 0 | $0 | $43,323 |
| WILSON ROBERT N | director | 1 | $12,915 | 0 | $0 | $12,915 |
| Leheny A. Rachel | CHIEF EXECUTIVE OFFICER | 2 | $9,575 | 0 | $0 | $9,575 |
| Stauderman Kenneth A. | Chief Scientific Officer | 2 | $5,810 | 1 | $3,650 | $2,160 |
| Bardin Stephen | Chief Financial Officer | 1 | $3,005 | 0 | $0 | $3,005 |
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Over the last 12 months, insiders at CalciMedica, Inc. have bought $212,650 and sold $3,650 worth of CalciMedica, Inc. stock.
On average, over the past 5 years, insiders at CalciMedica, Inc. have bought $1.75M and sold $3,650 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Roberts Eric W (CHIEF BUSINESS OFFICER) — $147,271. Hebbar Sudarshan (Chief Medical Officer) — $43,323. WILSON ROBERT N (director) — $12,915.
The last purchase of 2,500 shares for transaction amount of $7,675 was made by Roberts Eric W (CHIEF BUSINESS OFFICER) on 2025‑09‑18.
| 2025-09-18 | Roberts Eric W | CHIEF BUSINESS OFFICER | 2,500 0.0171% | $3.07 | $7,675 | -69.16% | ||
| 2025-09-15 | Roberts Eric W | CHIEF BUSINESS OFFICER | 3,400 0.0229% | $2.68 | $9,105 | -60.18% | ||
| 2025-09-12 | Roberts Eric W | CHIEF BUSINESS OFFICER | 5,000 0.0352% | $3.12 | $15,600 | -60.57% | ||
| 2025-09-09 | Roberts Eric W | CHIEF BUSINESS OFFICER | 2,343 0.0147% | $3.15 | $7,378 | -18.85% | ||
| 2025-08-29 | Roberts Eric W | CHIEF BUSINESS OFFICER | 800 0.0058% | $2.74 | $2,192 | +10.37% | ||
| 2025-08-28 | Roberts Eric W | CHIEF BUSINESS OFFICER | 9,200 0.0691% | $2.86 | $26,340 | +8.79% | ||
| 2025-08-20 | Roberts Eric W | CHIEF BUSINESS OFFICER | 2,000 0.0142% | $2.72 | $5,440 | +5.45% | ||
| 2025-08-19 | Hebbar Sudarshan | Chief Medical Officer | 9,563 0.0694% | $2.82 | $26,962 | +3.78% | ||
| 2025-08-19 | Roberts Eric W | CHIEF BUSINESS OFFICER | 1,000 0.0072% | $2.79 | $2,790 | +3.78% | ||
| 2025-08-15 | Roberts Eric W | CHIEF BUSINESS OFFICER | 5,076 0.0362% | $2.90 | $14,709 | -0.86% | ||
| 2025-08-15 | Hebbar Sudarshan | Chief Medical Officer | 4,392 0.0302% | $2.79 | $12,267 | -0.86% | ||
| 2025-08-14 | Hebbar Sudarshan | Chief Medical Officer | 1,584 0.0112% | $2.58 | $4,095 | +11.11% | ||
| 2025-07-28 | Stauderman Kenneth A. | Chief Scientific Officer | 1,000 0.0076% | $3.96 | $3,960 | -21.56% | ||
| 2025-07-25 | Sale | Stauderman Kenneth A. | Chief Scientific Officer | 1,000 0.0069% | $3.65 | $3,650 | -23.42% | |
| 2025-07-22 | Roberts Eric W | CHIEF BUSINESS OFFICER | 1,500 0.0107% | $3.77 | $5,663 | -22.22% | ||
| 2025-07-21 | Roberts Eric W | CHIEF BUSINESS OFFICER | 1,500 0.0104% | $3.37 | $5,055 | -15.76% | ||
| 2025-07-21 | Leheny A. Rachel | CHIEF EXECUTIVE OFFICER | 1,000 0.0081% | $3.40 | $3,400 | -15.76% | ||
| 2025-07-18 | WILSON ROBERT N | director | 4,500 0.0307% | $2.87 | $12,915 | -1.99% | ||
| 2025-07-18 | Roberts Eric W | CHIEF BUSINESS OFFICER | 2,000 0.0137% | $2.88 | $5,760 | -1.99% | ||
| 2025-07-14 | Roberts Eric W | CHIEF BUSINESS OFFICER | 6,500 0.0488% | $2.43 | $15,810 | +26.72% |
| WILSON ROBERT N | director | 422029 2.6714% | $376,238.85 | 5 | 0 | <0.0001% |
| Roberts Eric W | CHIEF BUSINESS OFFICER | 84150 0.5327% | $75,019.73 | 25 | 0 | <0.0001% |
| Hebbar Sudarshan | Chief Medical Officer | 61539 0.3895% | $54,862.02 | 3 | 0 | |
| Stauderman Kenneth A. | Chief Scientific Officer | 12944 0.0819% | $11,539.58 | 2 | 1 | |
| Leheny A. Rachel | CHIEF EXECUTIVE OFFICER | 3500 0.0222% | $3,120.25 | 4 | 0 | <0.0001% |
| Bardin Stephen | Chief Financial Officer | 3000 0.019% | $2,674.50 | 2 | 0 | |
| ING GROEP NV | 1755683 11.1133% | $1.57M | 1 | 0 | ||
| HOVDE ERIC D | 10 percent owner | 1645000 10.4127% | $1.47M | 29 | 0 | |
| MELLON HBV ALTERNATIVE STRATEGIES LLC | 10 percent owner | 1003768 6.3538% | $894,859.17 | 20 | 11 | |
| Sanderling Venture Partners VI LP | 10 percent owner | 946744 5.9928% | $844,022.28 | 1 | 0 | <0.0001% |
| Sanderling Venture Partners VI Co Investment Fund LP | 10 percent owner | 814300 5.1544% | $725,948.45 | 1 | 0 | <0.0001% |
| Pacini Raymond J | CEO & President | 471675 2.9857% | $420,498.26 | 15 | 2 | |
| MIDDLETON FRED A | 36514 0.2311% | $32,552.23 | 3 | 0 | <0.0001% | |
| CREDIT SUISSE FIRST BOSTON/ | 10 percent owner | 0 0% | $0 | 0 | 1 | |
| Jarvis David R | 10 percent owner | 0 0% | $0 | 9 | 11 |
$8,253,997 | 122 | -53.40% | $14.48M | |
$437,045 | 47 | -21.69% | $13.11M | |
$94,610,184 | 33 | -23.48% | $17.96M | |
$555,628 | 21 | 43.52% | $12.77M | |
$114,619,342 | 20 | -7.41% | $14.79M | |
$61,586 | 19 | -35.67% | $12.55M | |
$91,696,644 | 18 | -4.72% | $19.16M | |
CalciMedica, Inc. (CALC) | $6,733,543 | 17 | -19.02% | $14.08M |
$1,246,170 | 12 | 65.67% | $15.37M | |
$389,864 | 11 | 12.52% | $14.41M | |
$20,759,738 | 11 | -44.68% | $11.08M | |
$120,379 | 10 | -24.48% | $11.52M | |
$3,899,715 | 10 | -39.18% | $13.99M | |
$13,595,542 | 9 | -16.74% | $17.97M | |
$8,971,546 | 8 | 6.18% | $13.9M | |
$206,317 | 7 | -29.23% | $13.1M | |
$8,470,804 | 6 | -13.28% | $17.48M | |
$147,504 | 5 | -36.70% | $11.56M | |
$18,186,879 | 4 | 49.41% | $18.78M |
| Increased Positions | 12 | +30.77% | 282,534 | +8.03% |
| Decreased Positions | 14 | -35.9% | 94,220 | -2.68% |
| New Positions | 7 | New | 220,647 | New |
| Sold Out Positions | 6 | Sold Out | 36,970 | Sold Out |
| Total Postitions | 37 | -5.13% | 4M | +5.35% |
| Deerfield Management Company, L.P. | $8,762.00 | 9.29% | 1.3M | 0 | 0% | 2025-09-30 |
| Soleus Capital Management, L.P. | $4,610.00 | 4.89% | 683,904 | -100,000 | -12.76% | 2025-09-30 |
| Aisling Capital Management Lp | $3,512.00 | 3.72% | 521,114 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $2,538.00 | 2.69% | 376,624 | +37,476 | +11.05% | 2025-09-30 |
| Geode Capital Management, Llc | $666.00 | 0.71% | 98,852 | +1,820 | +1.88% | 2025-09-30 |
| Envestnet Asset Management Inc | $517.00 | 0.55% | 76,705 | -16,728 | -17.9% | 2025-09-30 |
| Renaissance Technologies Llc | $472.00 | 0.5% | 70,000 | +34,000 | +94.44% | 2025-09-30 |
| Meritage Portfolio Management | $415.00 | 0.44% | 61,539 | +15,539 | +33.78% | 2025-09-30 |
| Stonehage Fleming Financial Services Holdings Ltd | $362.00 | 0.38% | 53,703 | +53,703 | New | 2025-09-30 |
| Sheets Smith Investment Management | $344.00 | 0.37% | 51,100 | +51,100 | New | 2025-09-30 |